[Stage I seminoma and radiotherapy: to bury it or not?]

Cancer Radiother. 2008 Dec;12(8):842-7. doi: 10.1016/j.canrad.2008.07.015. Epub 2008 Aug 28.
[Article in French]

Abstract

Postorchidectomy management of stage I testis seminoma has evolved for many years. Three treatment options should be discussed after surgery. Surveillance tends toward taking a more significant place to avoid overtreatment, adjuvant chemotherapy with carboplatin has demonstrated its efficiency, and for some, preventive radiotherapy, the historical reference treatment, is losing momentum. Whatever the chosen orientation, long-term prognosis is excellent with overall survival closed to 100%. In this context, this review underlines the advantages and the drawbacks of the three attitudes but also the unknowns relative to each. Indeed, their knowledge is crucial for informing clearly and with an objective way. Without gold-standard, but with three therapeutic options available, informing our patients is the key so they make an informed choice in dialogue with the oncologist.

Publication types

  • English Abstract

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Carboplatin / therapeutic use
  • Combined Modality Therapy
  • Humans
  • Male
  • Neoplasm Staging
  • Orchiectomy*
  • Seminoma / drug therapy
  • Seminoma / mortality
  • Seminoma / pathology*
  • Seminoma / radiotherapy*
  • Seminoma / surgery
  • Survival Rate
  • Testicular Neoplasms / drug therapy
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / radiotherapy*
  • Testicular Neoplasms / surgery

Substances

  • Antineoplastic Agents
  • Carboplatin